Sepragen Announces the Launch of Quantasep 3000 SU System

October 14, 2012, Hayward, CA ... Sepragen Corporation announced the launch of its much awaited bench scale single use chromatography system, Quantasep 3000 SU. The system is designed to meet the growing needs of biotech companies that need to make clinical material particularly antibodies from cell culture.

It consists of a pre-sterilized, completely disposable flow-path which can be easily changed out after a run eliminating the need to clean the system and then validate that the cleaning did not result in carryover from one batch to the next. Thus uptime can be maximized and the risk of cross contamination minimized. The disposable flow-path consists of tubing and requisite sensors.

The Quanatasep 3000 SU system is capable of delivering up to 3 Lpm flow rate on either of its dual peristaltic pumps. It has up to 8 inlets for buffers, 6 fractions, UV, conductivity, pH, air, pressure and leak sensors. It is capable of generating gradients and is powered by the very intuitive PC driven Quantasep software that enables manual and automated protocol driven automation, data analysis and cGMP report generation. The system is compact and takes up very little of the premium space in purification suites. It is attractively designed in a stainless steel enclosure which is easily cleaned. It can easily be mounted on a cart for transportability. For more information call Sepragen Corporation at 510-475-0650.

Return to News and Events main page

The statements in this release that relate to future events or performance, statements about growth, future regulatory clearances, levels of sales and market size and future manufacturing capacity and efficiencies are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to the development of markets for and commercial acceptance of the company's products and services, the availability of components, competitors' product introductions and other risks identified in the company's SEC filings. Actual results may differ from those described in these forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.